Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.

A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or nevirapine was conducted to evalu...

Full description

Bibliographic Details
Main Authors: Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Julia Double, Charles Gilks, Cynthia C McCoig, Paula Munderi, Godfrey Musoro, Cissy M Kityo, Heiner Grosskurth, James Hakim, Peter N Mugyenyi, Amy Cutrell, Teodora Perger, Mark S Shaefer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0225199

Internet

https://doi.org/10.1371/journal.pone.0225199

Similar Items